Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Feng, Jun; Sun, Xuguo

doi:10.1007/s15010-018-1149-x

Cited by 48 publications

(49 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If operated on early, less lung tissue would require resection (ie, an early wedge resection could preempt a later lobectomy). Multilobar involvement was seen more frequently in the study by Lin et al and in numbers similar to ours in the study by Feng and Sun . Our study noted upper lobe predilection, favouring the RUL over the LUL, replicating what has been seen in other studies .…”

Section: Discussionsupporting

confidence: 91%

“…The clinical presentation of PM is non‐specific and cannot be reliably used in isolation to diagnose PM or distinguish it from other IFIs. Akin to published studies, fever and cough were the most frequently reported symptoms in our study . The relative lesser frequency of hemoptysis, pleuritic chest pain and dyspnoea/hypoxia is also comparable to what has been described in the literature but should still raise suspicion for IFI when present …”

Section: Discussionsupporting

confidence: 90%

“…Multilobar involvement was seen more frequently in the study by Lin et al and in numbers similar to ours in the study by Feng and Sun . Our study noted upper lobe predilection, favouring the RUL over the LUL, replicating what has been seen in other studies . Chamilos et al found that the presence of multiple (≥10) nodules had increased odds of being PM but only one of our patients (patient #7) had this finding.…”

Section: Discussionsupporting

confidence: 89%

“…However, this has been challenged by evidence from multiple other studies. Some studies have demonstrated the relative rarity of RHS in PM . Other publications have drawn attention to both infectious and non‐infectious causes of RHS other than PM, including bacterial pneumonia, tuberculosis, cryptococcosis, cryptogenic organising pneumonia, granulomatosis with polyangiitis, sarcoidosis and malignancy .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Cut it out! Thoracic surgeon’s approach to pulmonary mucormycosis and the role of surgical resection in survival

Multani

Reveron-Thornton

Garvert

et al. 2019

Mycoses

View full text Add to dashboard Cite

Background: Mucormycosis portends a poor prognosis with mortality rates ranging from 50% to 70% in pulmonary mucormycosis (PM) and up to 95% in disseminated disease. However, detailed outcomes data have been lacking. It remains unknown how to identify patients who would benefit from surgical resection. Objectives:We present our experience with patients undergoing surgical resection for PM, including an analysis of factors affecting postoperative survival. We also describe a thoracic surgeon's approach through illustrative cases. Patients/Methods: We conducted a single-centre retrospective study of all adult patients with PM who received antifungal therapy and underwent surgical resection or who Results: Twelve patients received antifungal therapy and underwent surgical resection and 13 patients received antifungal therapy alone. From infection onset to death (or right-censoring if still alive), patients who underwent surgical resection had a median survival of 406 days (mean, 561.3; range, 22-2510), and patients who received antifungal therapy alone had a median survival of 28 days (mean, 66.7; range, 8-447).In patients who underwent surgical resection, median postoperative survival time was 154 days (range, 11-2495), in-hospital mortality was 16.7%, and 1-year mortality was 50.0%. Age, primary disease, ASA status, extrapulmonary dissemination, laterality, multilobar involvement, number of lesions, largest lesion size, platelet count, surgical approach, type of resection or extent of resection were not significantly associated with postoperative survival. Conclusions:Surgical resection significantly increases survival and should be strongly considered for selected patients with PM.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cut it out! Thoracic surgeon’s approach to pulmonary mucormycosis and the role of surgical resection in survival

Multani

Reveron-Thornton

Garvert

et al. 2019

Mycoses

View full text Add to dashboard Cite

show abstract

“…Pulmonary type is the second most common site of involvement and often seen in patients with haematological disorders and transplant recipients [4,5]. Haematological malignancy was the major risk factor (32–40%), followed by diabetes mellitus (32–56%), haematopoietic stem cell transplant (1–9.8%) and solid organ transplant (6.5–9%) and renal disease (13–18%) in pulmonary mucormycosis [129,130,131]. Prakash et al reported post-pulmonary tuberculosis (21%) as one of the risk factors for pulmonary mucormycosis [5].…”

Section: Clinical Forms Of Mucormycosismentioning

confidence: 99%

Global Epidemiology of Mucormycosis

Prakash

Chakrabarti

2019

JoF

733

753

View full text Add to dashboard Cite

Mucormycosis is an angio-invasive fungal infection, associated with high morbidity and mortality. A change in the epidemiology of mucormycosis has been observed in recent years with the rise in incidence, new causative agents and susceptible population. The rise has been perceived globally, but it is very high in the Asian continent. Though diabetes mellitus overshadow all other risk factors in Asia, post-tuberculosis and chronic renal failure have emerged as new risk groups. The rhino-cerebral form of mucormycosis is most commonly seen in patients with diabetes mellitus, whereas, pulmonary mucormycosis in patients with haematological malignancy and transplant recipients. In immunocompetent hosts, cutaneous mucormycosis is commonly seen following trauma. The intriguing clinical entity, isolated renal mucormycosis in immunocompetent patients is only reported from China and India. A new clinical entity, indolent mucormycosis in nasal sinuses, is recently recognized. The causative agents of mucormycosis vary across different geographic locations. Though Rhizopus arrhizus is the most common agent isolated worldwide, Apophysomyces variabilis is predominant in Asia and Lichtheimia species in Europe. The new causative agents, Rhizopus homothallicus, Mucor irregularis, and Thamnostylum lucknowense are reported from Asia. In conclusion, with the change in epidemiology of mucormycosis country-wise studies are warranted to estimate disease burden in different risk groups, analyse the clinical disease pattern and identify the new etiological agents.

show abstract

Re-Emerging Systemic Mucormycosis Associated With COVID-19 Infection in Africa

Akinyosoye

Akinduti

2022

Green Energy and Technology

View full text Add to dashboard Cite

Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Cited by 48 publications

References 83 publications

Cut it out! Thoracic surgeon’s approach to pulmonary mucormycosis and the role of surgical resection in survival

Cut it out! Thoracic surgeon’s approach to pulmonary mucormycosis and the role of surgical resection in survival

Global Epidemiology of Mucormycosis

Re-Emerging Systemic Mucormycosis Associated With COVID-19 Infection in Africa

Contact Info

Product

Resources

About